Invitae Corporation Files Registration Statement for Proposed Initial Public Offering
January 9, 2015

SAN FRANCISCO —January 9, 2015—Invitae Corporation announced today that it has filed a registration statement on Form S‐1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Invitae intends to apply to list its common stock on The New York Stock Exchange under the symbol “NVTA.”

J.P. Morgan Securities LLC is acting as the sole book‐running manager for the offering. Cowen and Company, LLC and Leerink Partners LLC are acting as co‐managers.

This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (866) 803‐9204.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Invitae

Based in San Francisco, Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic test comprising over 200 genes for a variety of genetic disorders associated primarily with cancer, but also covering cardiology, hematology, neurology and pediatrics.

Copyright ? 2011 Decheng Capital LLC. All Rights Reserved.
浙江20选5预测推荐 宝星棋牌代理 广东好彩1肖玩法 江苏快三走势定牛 江苏体彩排列5开奖结果查询 快速赛车走势图 幸运飞艇开奖直播 2020mba招生简章 现在理财收益低 新濠天地赌场怎么样 浙江体彩6加1中奖规则 同创娱乐平台用户登录 七乐彩杀号定胆 舟山飞鱼开奖走势图 广西快乐10分网址客户端 网上棋牌真钱可信吗 安徽时时彩计划软件一首页